The price of Opzelura cream varies depending on factors such as the dosage, quantity, and pharmacy. Specific pricing details are generally not publicly disclosed and are best obtained directly from pharmacies or through insurance provider resources.
What is Opzelura and what is it used for?
Opzelura (ruxolitinib) cream is a prescription medication used to treat atopic dermatitis (eczema) and vitiligo. It is a topical Janus kinase (JAK) inhibitor that works by reducing inflammation and repigmenting skin in the case of vitiligo [1].
How does Opzelura work?
Opzelura cream contains ruxolitinib, which inhibits the activity of Janus kinases (JAKs). These enzymes play a role in the inflammatory pathways that contribute to atopic dermatitis and the loss of pigment in vitiligo. By blocking JAKs, ruxolitinib helps to reduce inflammation and promote skin repigmentation [1].
What is the typical dosage for Opzelura cream?
Opzelura is typically applied to affected areas of the skin twice daily. The specific dosage strength and amount to be used will be determined by a healthcare professional based on the patient's condition and response to treatment [1].
What are the potential side effects of Opzelura cream?
Common side effects associated with Opzelura cream include upper respiratory tract infections, ear infections, acne, itching, and a worsening of atopic dermatitis. More serious, though less common, side effects can include serious infections, blood clots, certain cancers, and changes in cholesterol levels [1].
Are there any safety concerns or warnings associated with Opzelura?
The prescribing information for Opzelura includes boxed warnings regarding the risk of serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. Patients should discuss these risks thoroughly with their healthcare provider [1].
What is the patent status of Opzelura?
Information regarding the specific patent status and expiration dates for Opzelura can be found through resources like DrugPatentWatch.com. Patent information is crucial for understanding when generic versions of a drug might become available [2].
Who manufactures Opzelura?
Opzelura is manufactured by Incyte Corporation [1].